Acadia, page-294

Just finished listening to Acadia’s fireside chat at the JMP Securities Life Sciences Conference (link below). Main points:

* Daybue launch - 4 weeks in and all going to plan.
* Receiving enrolment forms from multiple streams of patients (males and females, clinical trial participants and new-to-drug patients, all age groups, all symptom severity groups etc) which is giving confidence to Acadia.
* Whilst Acadia does not have an early access program, there is a “Letter of Medical Exception” process which enables patients to get onto commercial supply in advance of payors making coverage decisions.
* 90% of the 80 patients on the Daffodil Open Label Extension study have started the process of rolling over to commercial supply and the payor approval process for these patients should be complete in 2-3
months.
* Some treating doctors in the academic institutions will prescribe Daybue for hundreds of Rett patients. Given that many of the patients don’t even live in the same state, the doctors are not going to be able to see them all “after lunch on Monday” to prescribe, so the process may take awhile for these patients.
* Acadia hopes to recruit 800 - 900 Rett patients to the real world study of Daybue.

https://wsw.com/webcast/jmp59/acad/1635357